TKG Advisors LLC Invests $5.15 Million in Gilead Sciences, Inc. $GILD

TKG Advisors LLC purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 46,480 shares of the biopharmaceutical company’s stock, valued at approximately $5,153,000. Gilead Sciences makes up about 2.3% of TKG Advisors LLC’s portfolio, making the stock its 16th largest position.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. EPG Wealth Management LLC raised its stake in shares of Gilead Sciences by 2.0% during the second quarter. EPG Wealth Management LLC now owns 4,627 shares of the biopharmaceutical company’s stock valued at $513,000 after acquiring an additional 89 shares in the last quarter. Southland Equity Partners LLC raised its holdings in shares of Gilead Sciences by 2.9% in the second quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock valued at $364,000 after acquiring an additional 92 shares in the last quarter. Putney Financial Group LLC raised its holdings in shares of Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 94 shares in the last quarter. Twelve Points Wealth Management LLC boosted its position in Gilead Sciences by 1.5% during the second quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company’s stock valued at $721,000 after purchasing an additional 98 shares in the last quarter. Finally, Advantage Trust Co boosted its position in Gilead Sciences by 13.6% during the second quarter. Advantage Trust Co now owns 838 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 100 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on GILD shares. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Wolfe Research lifted their price target on shares of Gilead Sciences from $135.00 to $140.00 and gave the stock an “outperform” rating in a report on Thursday, October 23rd. Morgan Stanley upped their target price on Gilead Sciences from $143.00 to $147.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. BMO Capital Markets upped their target price on Gilead Sciences from $130.00 to $135.00 and gave the company an “outperform” rating in a research report on Monday, October 20th. Finally, TD Cowen upped their target price on Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $125.08.

Gilead Sciences Price Performance

Shares of GILD opened at $123.00 on Wednesday. The business’s 50-day moving average is $115.98 and its two-hundred day moving average is $111.92. The company has a market capitalization of $152.62 billion, a P/E ratio of 24.50, a P/E/G ratio of 0.81 and a beta of 0.34. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a fifty-two week low of $86.08 and a fifty-two week high of $124.61.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period last year, the firm earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a $0.79 dividend. The ex-dividend date is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio is 48.99%.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the completion of the transaction, the chief executive officer owned 591,203 shares in the company, valued at $66,013,726.98. This represents a 1.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the sale, the insider owned 114,168 shares of the company’s stock, valued at $13,532,333.04. This trade represents a 19.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 71,500 shares of company stock worth $8,336,040 in the last 90 days. Insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.